---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-058776"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:53:57.707756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics presents preclinical data on SMARCA2 and KAT6A degraders at AACR

## Summary
- PRT3789, a selective SMARCA2 degrader in Phase 1/2, shows deep SMARCA2 degradation and high selectivity over SMARCA4.
- KAT6A degraders demonstrate robust anti-cancer activity in preclinical breast and lung cancer models, including complete regressions.
- Prelude's KAT6A degraders show reduced hematologic toxicity compared to dual KAT6A/B inhibitors, potentially improving safety.
- SMARCA2 resynthesis rate is 2-3 times slower than SMARCA4, contributing to broad therapeutic index of PRT3789.
- KAT6A degraders disrupt HAT complex and affect ERα expression, showing activity in ESR1- and PI3Kα-mutant and resistant cells.

## SEC filing metadata
- accession: 0000950170-25-058776
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025058776/0000950170-25-058776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025058776/prld-20250425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-058776
- JSON: https://secwatch.observer/filing/0000950170-25-058776.json
- Plain text: https://secwatch.observer/filing/0000950170-25-058776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.